McLaren officially confirms their most track-focused road vehicle for 2018 debut
What The New "Krack" Wi-Fi Attack Really Means For You
Maharashtra transport employees' strike enters third day over pay
FDA Approves Cancer Gene Therapy from Gilead Science
HC Wainwright Downgrades Zynerba Pharmaceuticals to Hold
09 August 2017, 12:32 | Melissa Porter
Zynerbia is bidding to develop treatments for severe chronic health conditions
Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs. (ZYNE) stock price comparison to its moving averages, shares of company spotted the move of -15.58% isolated from the 50-day moving average and derived -13.35% away from 20-day moving average in the most recent session. Piper Jaffray Companies cut shares of Zynerba Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $42.00 to $7.00 in a report on Monday. On average, analysts expect that Zynerba Pharmaceuticals will post ($2.46) EPS for the current year.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings data on Tuesday, August 1st.
Zynerba Pharma CS (NASDAQ:ZYNE) shares traded on -55.71% down secure line and closed at $6.67. Finally, HC Wainwright set a $30.00 price target on shares of Zynerba Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, August 1st. (NASDAQ:ZYNE) from a sell rating to a hold rating in a research report sent to investors on Wednesday, July 12th. "(NASDAQ:ZYNE) Given a $8.00 Price Target at Oppenheimer Holdings, Inc." was originally published by StockNewsTimes and is owned by of StockNewsTimes. Zynerba Pharmaceuticals, Inc. The firm's market capitalization is $88.42 million. Finally, Jefferies Group LLC restated a "buy" rating and issued a $32.00 price objective on shares of Zynerba Pharmaceuticals in a research note on Thursday, May 25th. 1,077,420 shares of the stock were exchanged. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) notched a 12-month high of $32.25 while $42.00 target is by far the most aggressive out of analysts who are now evaluating ZYNE, $9.75 higher than the next highest 52-week price estimate. Accern also assigned media headlines about the company an impact score of 45.2667347720794 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Its up 0.02% from 2.21M shares, reported previously. The stock declined 0.82% or $0.07 reaching $8.45 on the news. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Analysts forecast EPS of $-0.60, up exactly $0.10 or 14.29 % from 2014's $-0.7 EPS. Canaccord Genuity initiated it with "Buy" rating and $35 target in Monday, September 14 report. The stock has slashed -19.16% to a low over the previous 12 months and showed declining move -74.30% to a high over the same period.
P/E of the company is not reported. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock. Essex Investment Mgmt Communication Limited Liability Company holds 0.16% or 106,490 shares.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base.
In a report released yesterday, Cantor Fitzgerald also downgraded the stock to Hold with a $4 price target. The stock has "Buy" rating by Oppenheimer on Monday, June 26. The firm earned "Hold" rating on Monday, August 7 by Maxim Group. The company was initiated on Thursday, March 17 by Roth Capital.
Banco Santander, SA (NYSE:SAN) Valuation According To Analysts
Finally, FIL Ltd acquired a new position in shares of Banco Santander-Chile during the first quarter valued at about $8,843,000. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock.